Concepedia

Lung Cancer Incidence in Never Smokers

Heather A. Wakelee, Ellen T. Chang, Scarlett Lin Gomez, Theresa H.M. Keegan, Diane Feskanich, Christina A. Clarke, Lars Holmberg, Lee C. Yong, Laurence N. Kolonel, Michael K. Gould,

Journal of Clinical Oncology · 2007 · 609 citations · 57 references

DOIFull text

Open access

Abstract

Lung cancer in never smokers is an important public health issue, and further exploration of its incidence patterns, etiology, and biology is needed.

References

57

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine · 2005 · 5.4K citations · Full text

Cancer Statistics, 2006

Ahmedin Jemal, Rebecca L. Siegel, Elizabeth M. Ward et al. · CA A Cancer Journal for Clinicians · 2006 · 5.3K citations · Full text

, , +17

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

William Pao, Vincent A. Miller, Maureen F. Zakowski et al. · Proceedings of the National Academy of Sciences · 2004 · 4.3K citations · Full text

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Nick Thatcher, Alex Y. Chang, Purvish M. Parikh et al. · The Lancet · 2005 · 2.1K citations

, , +6

Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

Ming‐Sound Tsao, Akira Sakurada, Jean-Claude Cutz et al. · New England Journal of Medicine · 2005 · 1.8K citations